https://pharminent.com/novartis-unveils-north-carolina-api-plant-as-final-piece-of-23b-us-expansion/ 2026-05-01T16:26:58Z Pharminent en Novartis unveils North Carolina API plant as final piece of $23B US expansion 2026-05-01T14:53:11Z Blog https://pharminent.com/amgen-positions-maritide-as-potential-best-monthly-obesity-drug/ 2026-05-01T16:27:01Z Pharminent en Amgen positions MariTide as potential 'best monthly' obesity drug 2026-05-01T12:44:14Z Blog https://pharminent.com/fdas-odac-delivers-one-loss-one-win-for-astrazeneca/ 2026-05-01T16:27:02Z Pharminent en FDA's ODAC delivers one loss, one win for AstraZeneca 2026-05-01T11:19:26Z Blog https://pharminent.com/axsome-receives-fda-approval-for-auvelity-to-treat-alzheimers-agitation/ 2026-05-01T16:27:03Z Pharminent en Axsome receives FDA approval for Auvelity to treat Alzheimer's agitation 2026-05-01T09:55:43Z Blog https://pharminent.com/leo-pharma-to-acquire-gene-therapy-company-replay/ 2026-05-01T16:27:03Z Pharminent en LEO Pharma to acquire gene therapy company Replay 2026-05-01T09:37:44Z Blog https://pharminent.com/eli-lilly-lifts-2026-revenue-guidance-as-q1-marks-dominant-opening/ 2026-05-01T16:27:04Z Pharminent en Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening 2026-05-01T09:32:32Z Blog https://pharminent.com/bms-brings-the-buzz-around-late-stage-readouts-amid-a-so-so-q1/ 2026-05-01T16:27:05Z Pharminent en BMS brings the buzz around late-stage readouts amid a so-so Q1 2026-05-01T09:20:53Z Blog https://pharminent.com/where-gross-to-net-pressure-actually-lives-after-launch/ 2026-05-01T16:27:06Z Pharminent en Where Gross-to-net Pressure Actually Lives After Launch 2026-05-01T04:00:00Z Blog https://pharminent.com/two-biotechs-raise-a-combined-556m-in-latest-spurt-of-ipos/ 2026-05-01T16:27:06Z Pharminent en Two biotechs raise a combined $556M in latest spurt of IPOs 2026-05-01T02:03:00Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-april-30-2026/ 2026-04-30T21:02:43Z Pharminent en Rare Disease & Gene Therapy Digest • April 30, 2026 2026-04-30T21:02:39Z Blog https://pharminent.com/fda-approves-first-non-antipsychotic-drug-to-treat-agitation-associated-with-dementia/ 2026-05-01T16:22:26Z Pharminent en FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia 2026-04-30T18:52:35Z Blog https://pharminent.com/eligibility-for-medicare-savings-programs-for-specified-low-income-medicare-beneficiaries-slmbs/ 2026-05-01T16:22:29Z Pharminent en Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs) 2026-04-30T17:44:39Z Blog https://pharminent.com/eligibility-for-medicare-savings-programs-for-qualified-medicare-beneficiaries-qmbs/ 2026-05-01T16:22:31Z Pharminent en Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs) 2026-04-30T17:37:05Z Blog https://pharminent.com/eligibility-for-medicare-savings-programs-for-qualifying-individuals-qis/ 2026-05-01T16:22:31Z Pharminent en Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs) 2026-04-30T17:29:28Z Blog https://pharminent.com/average-drug-fills-and-average-gross-drug-costs-per-medicare-part-d-enrollee/ 2026-05-01T16:22:32Z Pharminent en Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee 2026-04-30T17:29:03Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-30-2026/ 2026-04-30T17:08:27Z Pharminent en Strategic News Watch • April 30, 2026 2026-04-30T17:08:23Z Blog https://pharminent.com/merck-still-sees-compelling-outlook-for-terns-leukemia-drug/ 2026-05-01T16:22:33Z Pharminent en Merck still sees 'compelling' outlook for Terns leukemia drug 2026-04-30T16:21:00Z Blog https://pharminent.com/parexel-buys-vitrana-to-boost-patient-safety-toolkit/ 2026-05-01T16:22:35Z Pharminent en Parexel buys Vitrana to boost patient safety toolkit 2026-04-30T16:09:20Z Blog https://pharminent.com/uniqure-in-symbolic-win-to-seek-uk-approval-of-huntingtons-gene-therapy/ 2026-05-01T16:22:37Z Pharminent en UniQure, in 'symbolic' win, to seek UK approval of Huntington's gene therapy 2026-04-30T15:55:00Z Blog https://pharminent.com/lilly-posts-another-blowout-quarter-as-focus-turns-to-foundayo-launch/ 2026-05-01T16:22:38Z Pharminent en Lilly posts another 'blowout quarter' as focus turns to Foundayo launch 2026-04-30T15:26:00Z Blog https://pharminent.com/market-access/market-access-intelligence-midweek-update-april-29-2026/ 2026-04-30T12:40:17Z Pharminent en Market Access Intelligence • Midweek Update • April 29, 2026 2026-04-30T12:40:14Z Blog https://pharminent.com/lilly-clocks-56-revenue-increase-in-q1-but-declining-prices-stunt-growth/ 2026-04-30T13:23:50Z Pharminent en Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth 2026-04-30T12:07:45Z Blog https://pharminent.com/teva-makes-its-first-ma-play-in-years-buying-emalex/ 2026-04-30T13:23:12Z Pharminent en Teva makes its first M&A play in years, buying Emalex 2026-04-30T11:50:14Z Blog https://pharminent.com/astrazeneca-prunes-asthma-rare-disease-pipeline-cultivates-cancer-portfolio/ 2026-04-30T13:27:21Z Pharminent en AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio 2026-04-30T11:41:20Z Blog https://pharminent.com/gsk-partnered-alector-hit-with-third-neuro-failure-as-alzheimers-asset-disappoints/ 2026-04-30T13:24:22Z Pharminent en GSK-partnered Alector hit with third neuro failure as Alzheimer's asset disappoints 2026-04-30T11:27:58Z Blog https://pharminent.com/norgine-gets-first-eu-approval-for-whim-syndrome-therapy/ 2026-04-30T13:20:39Z Pharminent en Norgine gets first EU approval for WHIM syndrome therapy 2026-04-30T09:36:27Z Blog https://pharminent.com/regeneron-q1-2026-net-income-falls-10-to-727m/ 2026-04-30T13:19:51Z Pharminent en Regeneron Q1 2026 net income falls 10% to $727m 2026-04-30T09:22:58Z Blog https://pharminent.com/ray-therapeutics-receives-ema-prime-status-for-gene-therapy-2/ 2026-04-30T13:10:58Z Pharminent en Ray Therapeutics receives EMA PRIME status for gene therapy 2026-04-30T09:21:15Z Blog https://pharminent.com/survodutide-delivers-16-6-weight-loss-in-major-phase-3-obesity-trial/ 2026-04-30T13:19:23Z Pharminent en Survodutide delivers 16.6% weight loss in major phase 3 obesity trial 2026-04-30T09:08:40Z Blog https://pharminent.com/avalyn-in-pursuit-of-better-lung-drugs-banks-300m-in-an-ipo/ 2026-04-30T13:10:48Z Pharminent en Avalyn, in pursuit of better lung drugs, banks $300M in an IPO 2026-04-30T01:06:00Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-april-29-2026/ 2026-04-29T23:46:08Z Pharminent en Manufacturing Intelligence • Weekly Digest • April 29, 2026 2026-04-29T23:46:04Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-april-29-2026/ 2026-04-29T22:56:42Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • April 29, 2026 2026-04-29T22:56:38Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-29-2026/ 2026-04-29T18:39:31Z Pharminent en Strategic News Watch • April 29, 2026 2026-04-29T18:39:28Z Blog https://pharminent.com/pfizer-protects-6-4bn-heart-disease-blockbuster-from-generics-for-now/ 2026-04-30T13:09:43Z Pharminent en Pfizer protects $6.4bn heart disease blockbuster from generics, for now 2026-04-29T15:59:24Z Blog https://pharminent.com/chiesi-to-buy-kalvista-in-1-9b-deal-for-rare-disease-drug/ 2026-04-30T13:28:49Z Pharminent en Chiesi to buy KalVista in $1.9B deal for rare disease drug 2026-04-29T15:34:00Z Blog https://pharminent.com/fda-tests-out-real-time-clinical-trials-abbvie-closes-in-on-a-kras-biotech/ 2026-04-30T13:08:17Z Pharminent en FDA tests out 'real-time' clinical trials; AbbVie closes in on a KRAS biotech 2026-04-29T15:21:00Z Blog https://pharminent.com/flash-brief-pbm-reform-collides-with-mfn-pricing-as-midterm-politics-reshape-the-drug-pricing-landscape/ 2026-04-30T12:46:35Z Pharminent en Flash Brief: PBM Reform Collides with MFN Pricing as Midterm Politics Reshape the Drug Pricing Landscape 2026-04-29T12:43:47Z Blog https://pharminent.com/pfizer-settles-with-generic-drugmakers-to-protect-blockbuster-drug-until-2031/ 2026-04-29T12:43:34Z Pharminent en Pfizer settles with generic drugmakers to protect blockbuster drug until 2031 2026-04-29T12:15:28Z Blog https://pharminent.com/az-amgen-will-pilot-fdas-real-time-clinical-trial-plan/ 2026-04-29T12:41:39Z Pharminent en AZ, Amgen will pilot FDA's real-time clinical trial plan 2026-04-29T12:03:58Z Blog https://pharminent.com/astrazeneca-faces-uphill-battle-at-upcoming-adcomm-in-face-of-fda-questions/ 2026-04-29T12:43:44Z Pharminent en AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions 2026-04-29T11:27:30Z Blog https://pharminent.com/generic-of-novos-glp-1-arrives-in-canada-a-test-case-for-the-world/ 2026-04-29T12:44:43Z Pharminent en Generic of Novo's GLP-1 arrives in Canada, a 'test case for the world' 2026-04-29T11:26:27Z Blog https://pharminent.com/eli-lilly-bets-on-recombinases-in-2-25bn-profluent-rd-pact/ 2026-04-29T12:44:54Z Pharminent en Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact 2026-04-29T10:51:54Z Blog https://pharminent.com/the-strategic-investments-expanding-cdmo-capabilities-for-hpapis-and-adcs/ 2026-04-29T12:36:16Z Pharminent en The strategic investments expanding CDMO capabilities for HPAPIs and ADCs 2026-04-29T10:42:51Z Blog https://pharminent.com/novartis-q1-sales-miss-hints-at-industrys-utilisation-of-ma-remedies/ 2026-04-29T12:37:34Z Pharminent en Novartis' Q1 sales miss hints at industry's utilisation of M&A remedies 2026-04-29T10:18:12Z Blog https://pharminent.com/arcera-and-fosun-sign-mou-for-neuroscience-innovation/ 2026-04-29T12:37:34Z Pharminent en Arcera and Fosun sign MoU for neuroscience innovation 2026-04-29T10:11:27Z Blog https://pharminent.com/rocket-to-sell-prv-for-180m-to-advance-gene-therapy-pipeline/ 2026-04-29T12:37:34Z Pharminent en Rocket to sell PRV for $180m to advance gene therapy pipeline 2026-04-29T09:55:00Z Blog